Breast Cancer Expert Nancy Davidson Elected ASCO President for 2007-2008

Publication
Article
OncologyONCOLOGY Vol 20 No 7
Volume 20
Issue 7

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

In addition, Bruce J. Roth, MD, professor of medicine/urologic surgery at Vanderbilt-Ingram Cancer Center, was elected secretary-treasurer for the 2006-2009 term. Five new members were elected to the ASCO board of directors (Howard A. Burris III, MD, Waun Ki Hong, MD, FACP, DMSC, Thomas Marsland, MD, Gregory H. Reaman, MD, and Martine J. Piccart-Gebhart, MD, PHD) and two new members to the ASCO nominating committee (Edith Perez, MD, and Eric P. Winer, MD), all for 3‑year terms beginning in June 2006.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content